United Therapeutics Corporation $UTHR Shares Acquired by Sivia Capital Partners LLC

Sivia Capital Partners LLC increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 247.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,105 shares of the biotechnology company’s stock after buying an additional 1,500 shares during the quarter. Sivia Capital Partners LLC’s holdings in United Therapeutics were worth $1,026,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. CIBC Asset Management Inc grew its holdings in shares of United Therapeutics by 30.1% during the fourth quarter. CIBC Asset Management Inc now owns 2,116 shares of the biotechnology company’s stock valued at $1,031,000 after buying an additional 490 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of United Therapeutics by 27.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 110,774 shares of the biotechnology company’s stock valued at $53,975,000 after buying an additional 23,938 shares in the last quarter. Westpac Banking Corp purchased a new position in shares of United Therapeutics during the fourth quarter valued at $719,000. Peak Retirement Planning Inc. purchased a new position in shares of United Therapeutics during the fourth quarter valued at $2,719,000. Finally, Natixis Advisors LLC grew its holdings in shares of United Therapeutics by 0.5% during the fourth quarter. Natixis Advisors LLC now owns 11,768 shares of the biotechnology company’s stock valued at $5,734,000 after buying an additional 53 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 605,743 shares of company stock valued at $340,981,769. Corporate insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of research analyst reports. Bank of America lifted their price target on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. UBS Group lifted their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Finally, Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Stock Performance

UTHR opened at $549.47 on Thursday. The company has a market cap of $23.33 billion, a PE ratio of 20.28, a price-to-earnings-growth ratio of 1.75 and a beta of 0.57. The stock has a 50-day moving average of $567.74 and a 200-day moving average of $518.04. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the company posted $6.63 EPS. On average, research analysts predict that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.